AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01145664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal concentrate-granules plus western therapy
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Study NCT01145664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduning Injection plus western therapy
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Study NCT01145664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Study NCT00484770 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Brain Natriuretic Peptide Levels -- Diagnostic testing
Study NCT00484770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical assessment
Study NCT01348724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] NKTR-118
Description: Single 25 mg oral dose administered on Day 1
Study NCT02492893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Study NCT02855489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attitudes Only
Study NCT02855489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Norms Only
Study NCT02855489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceived Behavioral Control Only
Study NCT02855489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intentions Only
Study NCT02855489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Constructs
Study NCT02855489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Constructs
Study NCT04809441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet change
Description: A specific very low-calorie diet (\<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
Study NCT01404429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
Study NCT01404429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
Study NCT04662229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eco-guided Percutaneous Electrical Stimulation
Description: Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.
Study NCT04662229 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
Study NCT02830477 — intervention group
Intervention type: BIOLOGICAL
Intervention: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Description: unmodified, full length recombinant FVIII
Study NCT04058275 — intervention group
Intervention type: OTHER
Intervention: Draw blood (phlebotomy, 83 ml)
Description: Draw 83 ml of blood
Study NCT03752970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spesolimab
Description: Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
Study NCT03752970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
Study NCT03752970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
Study NCT02583529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Back Tibial Nerve Electrostimulation
Description: The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
Study NCT02583529 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Electrostimulation
Description: The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
Study NCT01013038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration followed by stent implantation
Description: Export aspiration catheter 6F (Medtronics)
Study NCT01013038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional PCI
Description: balloon angioplasty and/or stent implantation
Study NCT03556800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel
Description: Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel
Study NCT03556800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogel
Description: Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel
Study NCT02200653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of MICARDIS®, once daily
Study NCT02200653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of MICARDIS®, once daily
Study NCT02200653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of COZAAR® / LORZAAR®, once daily
Study NCT02200653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of COZAAR® / LORZAAR®, once daily
Study NCT02200653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02200653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00368927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally
Study NCT00368927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT04654572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric measurement
Description: Myotonometric assessment can predict the muscle stiffness, tone and elasticity
Study NCT00878826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation.
Study NCT02985840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
Study NCT02985840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
Study NCT02985840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
Study NCT00144495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: 3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
Study NCT00144495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: 36000IU(s.c.)/week for 12 weeks
Study NCT02595775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized A/F report
Description: Individualized A/F report containing 9 colonoscopy quality measures.
Study NCT02595775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individualized A/F report
Description: Individualized A/F report containing 9 colonoscopy quality measures.
Study NCT02595775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A/F report plus a high intensity intervention
Description: E.g. Master class in colonoscopy
Study NCT02595775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A/F report plus a low intensity intervention
Description: E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
Study NCT02595775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A/F report alone
Study NCT02294526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sardine diet
Description: Diet rich in sardine: 100g/day of sardine 5 times a week
Study NCT03235752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ301 300mg
Description: TJ301 300mg IV infusion
Study NCT03235752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ301 600mg
Description: TJ301 600mg IV infusion
Study NCT03235752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion
Study NCT04068233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacemaker stimulation mode
Description: Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
Study NCT02878707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraoperative dexmedetomidine infusion
Study NCT02878707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative dexmedetomidine infusion
Study NCT00624247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: routine HIV testing
Description: Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
Study NCT02912637 — intervention group
Intervention type: OTHER
Intervention: Hyperpolarized Xenon MRI
Description: MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
Study NCT02574169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alveolar recruitment maneuvers group 1
Description: Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM.
Study NCT02574169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alveolar recruitment maneuvers group 2
Description: Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM.
Study NCT02989402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: 15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
Study NCT00045799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole sodium bicarbonate immediate release PWD/FS
Study NCT00045799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine IV
Study NCT03714464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole apples
Description: 350 of whole apples containing 49g of available carbohydrate with 173ml water
Study NCT03714464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple puree
Description: 384g of apple puree containing 44g of available carbohydrates with 224 ml water
Study NCT03714464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Juice
Description: 338g apple juice containing 46g of available carbohydrate with 260 ml water
Study NCT02039778 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stem Cell Radiotherapy (ScRT) and Temozolomide
Description: Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin \& the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays).
Study NCT01275144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT01275144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01275144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Administered orally
Study NCT00152113 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic Stem Cell Transplantation
Description: Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
Study NCT00152113 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS
Study NCT00152113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: See intervention description
Description: Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
Study NCT02952690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope® with tip manipulated stylet
Description: The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
Study NCT02952690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope® with standard-curved tip
Description: The style is curved in accordance with the curve of GVL blade
Study NCT04009187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person wheelchair propulsion training program
Description: The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
Study NCT04009187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute education session
Description: Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
Study NCT00918593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
Study NCT00918593 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy according to hospital procedures.
Study NCT00918593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
Study NCT00970021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Intake of 60 ml placebo daily in addition to chemotherapy
Description: The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
Study NCT00970021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intake of 60 ml agaricus daily in addition to chemotherapy
Description: The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
Study NCT00397605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids (1:1 ratio of THC % CBD)
Description: Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
Study NCT04312243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide gas
Description: Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
Study NCT05501392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEPS-PreK
Description: Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
Study NCT05501392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS-PreK
Description: Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).